Exelixis Inc. diskutieren
Exelixis Inc.
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
35,27 €
0,11 %
Exelixis, Inc. (NASDAQ: EXEL) was upgraded by analysts at Stephens from an "equal weight" rating to an "overweight" rating. They now have a $60.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) was given a new $50.00 price target on by analysts at Jefferies Financial Group Inc.. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at HC Wainwright from $47.00 to $53.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Truist Financial Corporation from $55.00 to $56.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Morgan Stanley from $47.00 to $48.00. They now have an "overweight" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $45.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target lowered by analysts at Morgan Stanley from $48.00 to $46.00. They now have an "overweight" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target lowered by analysts at Truist Financial Corporation from $56.00 to $49.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target lowered by analysts at HC Wainwright from $53.00 to $46.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $47.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Morgan Stanley from $46.00 to $50.00. They now have an "overweight" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) was given a new $44.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $46.00 to $49.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Morgan Stanley from $44.00 to $45.00. They now have an "overweight" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at TD Cowen from $44.00 to $51.00. They now have a "buy" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Ratings data for EXEL provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Hasbro Inc. diskutieren